cold chain raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-04. Anything still debated is marked as such rather than presented as settled.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
The antigens are memorised by these cells so that subsequent exposure to the same type of antigens will stimulate a secondary response, in which a higher concentration of antibodies specific for the antigens are reproduced rapidly and efficiently in a short time for the elimination of the pathogen. Under specific circumstances, low doses of vaccines are given initially, followed by additional doses named booster doses. Boosters can effectively maintain the level of memory cells in the human body, hence extending a person's immunity.
There is evidence supporting the use of minoxidil as a safe and effective treatment for female pattern hair loss, and there is no significant difference in efficiency between 2% and 5% formulations. Finasteride was shown to be no more effective than placebo based on low-quality studies. The effectiveness of laser-based therapies is unclear. Bicalutamide, an antiandrogen, is another option for the treatment of female pattern hair loss.
Now EC 1.1.1.303, diacetyl reductase [(R)-acetoin forming] and EC 1.1.1.304, diacetyl reductase [(S)-acetoin forming] EC 1.1.1.6: glycerol dehydrogenase EC 1.1.1.7: propanediol-phosphate dehydrogenase EC 1.1.1.8: glycerol-3-phosphate dehydrogenase (NAD+) EC 1.1.1.9: D-xylulose reductase EC 1.1.1.10: L-xylulose reductase EC 1.1.1.11: D-arabinitol 4-dehydrogenase EC 1.1.1.12: L-arabinitol 4-dehydrogenase EC 1.1.1.13: L-arabinitol 2-dehydrogenase EC 1.1.1.14: L-iditol 2-dehydrogenase EC 1.1.1.15: D-iditol 2-dehydrogenase EC 1.1.1.16: galactitol 2-dehydrogenase EC 1.1.1.17: mannitol-1-phosphate 5-dehydrogenase EC 1.1.1.18: inositol 2-dehydrogenase EC 1.1.1.19: glucuronate reductase EC 1.1.1.20: glucuronolactone reductase EC 1.1.1.207: (-)-menthol dehydrogenase EC 1.1.1.208: (+)-neomenthol dehydrogenase EC 1.1.1.21: aldose reductase EC 1.1.1.22: UDP-glucose 6-dehydrogenase EC 1.1.1.222: (R)-4-hydroxyphenyllactate dehydrogenase EC 1.1.1.23: histidinol dehydrogenase| EC 1.1.1.24: quinate/shikimate dehydrogenase (NAD+) EC 1.1.1.25: shikimate dehydrogenase (NADP+) EC 1.1.1.26: glyoxylate reductase EC 1.1.1.27: L-lactate dehydrogenase EC 1.1.1.28: D-lactate dehydrogenase EC 1.1.1.29: glycerate dehydrogenase EC 1.1.1.30: 3-hydroxybutyrate dehydrogenase EC 1.1.1.31: 3-hydroxyisobutyrate dehydrogenase EC 1.1.1.32: mevaldate reductase EC 1.1.1.33: mevaldate reductase (NADPH) EC 1.1.1.34: hydroxymethylglutaryl-CoA reductase (NADPH) EC 1.1.1.35: 3-hydroxyacyl-CoA dehydrogenase EC 1.1.1.36: acetoacetyl-CoA reductase EC 1.1.1.37: malate dehydrogenase EC 1.1.1.38: malate dehydrogenase (oxaloacetate-decarboxylating) EC 1.1.1.39: malate dehydrogenase (decarboxylating) EC 1.1.1.40: malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+) EC 1.1.1.41: isocitrate dehydrogenase (NAD+) EC 1.1.1.42: isocitrate dehydrogenase (NADP+) EC 1.1.1.43: phosphogluconate 2-dehydrogenase EC 1.1.1.44: phosphogluconate dehydrogenase (NADP+-dependent, decarboxylating) EC 1.1.1.45: L-gulonate 3-dehydrogenase EC 1.1.1.46: L-arabinose 1-dehydrogenase EC 1.1.1.47: glucose 1-dehydrogenase [NAD(P)+)] EC 1.1.1.48: D-galactose 1-dehydrogenase EC 1.1.1.49: glucose-6-phosphate dehydrogenase (NADP+) EC 1.1.1.50: 3α-hydroxysteroid 3-dehydrogenase (Si-specific) EC 1.1.1.51: 3(or 17)β-hydroxysteroid dehydrogenase EC 1.1.1.52: 3α-hydroxycholanate dehydrogenase (NAD+) EC 1.1.1.53: 3α(or 20β)-hydroxysteroid dehydrogenase EC 1.1.1.54: allyl-alcohol dehydrogenase EC 1.1.1.55: lactaldehyde reductase (NADPH) EC 1.1.1.56: ribitol 2-dehydrogenase EC 1.1.1.57: fructuronate reductase EC 1.1.1.58: tagaturonate reductase EC 1.1.1.59: 3-hydroxypropionate dehydrogenase EC 1.1.1.60: 2-hydroxy-3-oxopropionate reductase EC 1.1.1.61: 4-hydroxybutyrate dehydrogenase EC 1.1.1.62: 17β-estradiol 17-dehydrogenase EC 1.1.1.63: testosterone 17β-dehydrogenase. Now EC 1.1.1.239, 3α(17β)-hydroxysteroid dehydrogenase (NAD+) EC 1.1.1.64: testosterone 17β-dehydrogenase (NADP+) EC 1.1.1.65: pyridoxine 4-dehydrogenase EC 1.1.1.66: ω-hydroxydecanoate dehydrogenase EC 1.1.1.67: mannitol 2-dehydrogenase EC 1.1.1.68: 5,10-methylenetetrahydrofolate reductase. Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.1.69: gluconate 5-dehydrogenase EC 1.1.1.70: D-glucuronolactone dehydrogenase. Now included with EC 1.2.1.3 aldehyde dehydrogenase (NAD+) EC 1.1.1.71: alcohol dehydrogenase [NAD(P)+] EC 1.1.1.72: glycerol dehydrogenase (NADP+) EC 1.1.1.73: octanol dehydrogenase EC 1.1.1.74: D-aminopropanol dehydrogenase (reaction due to EC 1.1.1.4 (R,R)-butanediol dehydrogenase) EC 1.1.1.75: (R)-aminopropanol dehydrogenase EC 1.1.1.76: (S,S)-butanediol dehydrogenase EC 1.1.1.77: lactaldehyde reductase EC 1.1.1.78: methylglyoxal reductase (NADH-dependent) EC 1.1.1.79: glyoxylate reductase (NADP+) EC 1.1.1.80: isopropanol dehydrogenase (NADP+) EC 1.1.1.81: hydroxypyruvate reductase EC 1.1.1.82: malate dehydrogenase (NADP+) EC 1.1.1.83: D-malate dehydrogenase (decarboxylating) EC 1.1.1.84: dimethylmalate dehydrogenase EC 1.1.1.85: 3-isopropylmalate dehydrogenase EC 1.1.1.86: ketol-acid reductoisomerase (NADP+) EC 1.1.1.87: homoisocitrate dehydrogenase EC 1.1.1.88: hydroxymethylglutaryl-CoA reductase EC 1.1.1.89: dihydroxyisovalerate dehydrogenase (isomerizing). Now included with EC 1.1.1.86 ketol-acid reductoisomerase EC 1.1.1.90: aryl-alcohol dehydrogenase EC 1.1.1.91: aryl-alcohol dehydrogenase (NADP+) EC 1.1.1.92: oxaloglycolate reductase (decarboxylating) EC 1.1.1.93: tartrate dehydrogenase EC 1.1.1.94: glycerol-3-phosphate dehydrogenase [NAD(P)+] EC 1.1.1.95: phosphoglycerate dehydrogenase EC 1.1.1.96: diiodophenylpyruvate reductase EC 1.1.1.97: 3-hydroxybenzyl-alcohol dehydrogenase EC 1.1.1.98: (R)-2-hydroxy-fatty-acid dehydrogenase EC 1.1.1.99: (S)-2-hydroxy-fatty-acid dehydrogenase EC 1.1.1.100: 3-oxoacyl-[acyl-carrier-protein] reductase EC 1.1.1.101: acylglycerone-phosphate reductase EC 1.1.1.102: 3-dehydrosphinganine reductase EC 1.1.1.103: L-threonine 3-dehydrogenase EC 1.1.1.104: 4-oxoproline reductase EC 1.1.1.105: all-trans-retinol dehydrogenase (NAD+) EC 1.1.1.106: pantoate 4-dehydrogenase EC 1.1.1.107: pyridoxal 4-dehydrogenase EC 1.1.1.108: carnitine 3-dehydrogenase EC 1.1.1.109: Now EC 1.3.1.28, 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase EC 1.1.1.110: aromatic 2-oxoacid reductase EC 1.1.1.111: 3-(imidazol-5-yl)lactate dehydrogenase EC 1.1.1.112: indanol dehydrogenase EC 1.1.1.113: L-xylose 1-dehydrogenase EC 1.1.1.114: apiose 1-reductase EC 1.1.1.115: ribose 1-dehydrogenase (NADP+) EC 1.1.1.116: D-arabinose 1-dehydrogenase (NAD+) EC 1.1.1.117: D-arabinose 1-dehydrogenase [NAD(P)+] EC 1.1.1.118: glucose 1-dehydrogenase (NAD+) EC 1.1.1.119: glucose 1-dehydrogenase (NADP+) EC 1.1.1.120: galactose 1-dehydrogenase (NADP+) EC 1.1.1.121: aldose 1-dehydrogenase (NAD+) EC 1.1.1.122: D-threo-aldose 1-dehydrogenase EC 1.1.1.123: sorbose 5-dehydrogenase (NADP+) EC 1.1.1.124: fructose 5-dehydrogenase (NADP+) EC 1.1.1.125: 2-deoxy-D-gluconate 3-dehydrogenase EC 1.1.1.126: 2-dehydro-3-deoxy-D-gluconate 6-dehydrogenase EC 1.1.1.127: 2-dehydro-3-deoxy-D-gluconate 5-dehydrogenase EC 1.1.1.128: The reaction described is covered by EC 1.1.1.264, L-idonate 5-dehydrogenase. EC 1.1.1.129: L-threonate 3-dehydrogenase EC 1.1.1.130: 3-dehydro-L-gulonate 2-dehydrogenase EC 1.1.1.131: mannuronate reductase EC 1.1.1.132: GDP-mannose 6-dehydrogenase EC 1.1.1.133: dTDP-4-dehydrorhamnose reductase EC 1.1.1.134: dTDP-6-deoxy-L-talose 4-dehydrogenase (NADP+) EC 1.1.1.135: GDP-6-deoxy-D-talose 4-dehydrogenase EC 1.1.1.136: UDP-N-acetylglucosamine 6-dehydrogenase EC 1.1.1.137: ribitol-5-phosphate 2-dehydrogenase EC 1.1.1.138: mannitol 2-dehydrogenase (NADP+) EC 1.1.1.139: polyol dehydrogenase (NADP+). Now included with EC 1.1.1.21 aldehyde reductase EC 1.1.1.140: sorbitol-6-phosphate 2-dehydrogenase EC 1.1.1.141: 15-hydroxyprostaglandin dehydrogenase (NAD+) EC 1.1.1.142: D-pinitol dehydrogenase EC 1.1.1.143: sequoyitol dehydrogenase EC 1.1.1.144: perillyl-alcohol dehydrogenase EC 1.1.1.145: 3β-hydroxy-Δ5-steroid dehydrogenase EC 1.1.1.146: 11β-hydroxysteroid dehydrogenase EC 1.1.1.147: 16α-hydroxysteroid dehydrogenase EC 1.1.1.148: estradiol 17α-dehydrogenase EC 1.1.1.149: 20α-hydroxysteroid dehydrogenase EC 1.1.1.150: 21-hydroxysteroid dehydrogenase (NAD+) EC 1.1.1.151: 21-hydroxysteroid dehydrogenase (NADP+) EC 1.1.1.152: 3α-hydroxy-5β-androstane-17-one 3α-dehydrogenase EC 1.1.1.153: sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming) EC 1.1.1.154: ureidoglycolate dehydrogenase EC 1.1.1.155: homoisocitrate dehydrogenase. The enzyme is identical to EC 1.1.1.87, homoisocitrate dehydrogenase EC 1.1.1.156: glycerol 2-dehydrogenase (NADP+) EC 1.1.1.157: 3-hydroxybutyryl-CoA dehydrogenase EC 1.1.1.158: Now EC 1.3.1.98, UDP-N-acetylmuramate dehydrogenase EC 1.1.1.159: 7α-hydroxysteroid dehydrogenase EC 1.1.1.160: dihydrobunolol dehydrogenase EC 1.1.1.161: The activity is part of EC 1.14.13.15, cholestanetriol 26-monooxygenase EC 1.1.1.162: erythrulose reductase EC 1.1.1.163: cyclopentanol dehydrogenase EC 1.1.1.164: hexadecanol dehydrogenase EC 1.1.1.165: 2-alkyn-1-ol dehydrogenase EC 1.1.1.166: hydroxycyclohexanecarboxylate dehydrogenase EC 1.1.1.167: hydroxymalonate dehydrogenase EC 1.1.1.168: 2-dehydropantolactone reductase (Re-specific) EC 1.1.1.169: 2-dehydropantoate 2-reductase EC 1.1.1.170: 3β-hydroxysteroid-4α-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.171: Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.1.172: 2-oxoadipate reductase EC 1.1.1.173: L-rhamnose 1-dehydrogenase EC 1.1.1.174: cyclohexane-1,2-diol dehydrogenase EC 1.1.1.175: D-xylose 1-dehydrogenase EC 1.1.1.176: 12α-hydroxysteroid dehydrogenase EC 1.1.1.177: glycerol-3-phosphate 1-dehydrogenase (NADP+) EC 1.1.1.178: 3-hydroxy-2-methylbutyryl-CoA dehydrogenase EC 1.1.1.179: D-xylose 1-dehydrogenase (NADP+, D-xylono-1,5-lactone-forming) EC 1.1.1.180: Now included with EC 1.1.1.131 mannuronate reductase EC 1.1.1.181: cholest-5-ene-3β,7α-diol 3β-dehydrogenase EC 1.1.1.182: Now included with EC 1.1.1.198 (+)-borneol dehydrogenase, EC 1.1.1.227 (-)-borneol dehydrogenase and EC 1.1.1.228 (+)-sabinol dehydrogenase EC 1.1.1.183: geraniol dehydrogenase (NADP+) EC 1.1.1.184: carbonyl reductase (NADPH) EC 1.1.1.185: L-glycol dehydrogenase EC 1.1.1.186: dTDP-galactose 6-dehydrogenase EC 1.1.1.187: GDP-4-dehydro-D-rhamnose reductase EC 1.1.1.188: prostaglandin-F synthase EC 1.1.1.189: prostaglandin-E2 9-reductase EC 1.1.1.190: indole-3-acetaldehyde reductase (NADH) EC 1.1.1.191: indole-3-acetaldehyde reductase (NADPH) EC 1.1.1.192: long-chain-alcohol dehydrogenase EC 1.1.1.193: 5-amino-6-(5-phosphoribosylamino)uracil reductase EC 1.1.1.194: coniferyl-alcohol dehydrogenase EC 1.1.1.195: cinnamyl-alcohol dehydrogenase EC 1.1.1.196: 15-hydroxyprostaglandin-D dehydrogenase (NADP+) EC 1.1.1.197: 15-hydroxyprostaglandin dehydrogenase (NADP+) EC 1.1.1.198: (+)-borneol dehydrogenase EC 1.1.1.199: (S)-usnate reductase EC 1.1.1.200: aldose-6-phosphate reductase (NADPH) EC 1.1.1.228: (+)-sabinol dehydrogenase EC 1.1.1.251: galactitol-1-phosphate 5-dehydrogenase EC 1.1.1.252: tetrahydroxynaphthalene reductase EC 1.1.1.253: Now EC 1.5.1.33, pteridine reductase EC 1.1.1.254: (S)-carnitine 3-dehydrogenase EC 1.1.1.255: mannitol dehydrogenase EC 1.1.1.256: fluoren-9-ol dehydrogenase EC 1.1.1.257: 4-(hydroxymethyl)benzenesulfonate dehydrogenase EC 1.1.1.258: 6-hydroxyhexanoate dehydrogenase EC 1.1.1.259: 3-hydroxypimeloyl-CoA dehydrogenase EC 1.1.1.260: sulcatone reductase EC 1.1.1.261: sn-glycerol-1-phosphate dehydrogenase EC 1.1.1.262: 4-hydroxythreonine-4-phosphate dehydrogenase EC 1.1.1.263: 1,5-anhydro-D-fructose reductase EC 1.1.1.264: L-idonate 5-dehydrogenase EC 1.1.1.265: 3-methylbutanal reductase EC 1.1.1.266: dTDP-4-dehydro-6-deoxyglucose reductase EC 1.1.1.267: 1-deoxy-D-xylulose-5-phosphate reductoisomerase EC 1.1.1.268: 2-(R)-hydroxypropyl-CoM dehydrogenase EC 1.1.1.269: 2-(S)-hydroxypropyl-CoM dehydrogenase EC 1.1.1.270: 3β-hydroxysteroid 3-dehydrogenase EC 1.1.1.271: GDP-L-fucose synthase EC 1.1.1.272: D-2-hydroxyacid dehydrogenase (NADP+) EC 1.1.1.273: vellosimine dehydrogenase EC 1.1.1.274: 2,5-didehydrogluconate reductase (2-dehydro-D-gluconate-forming) EC 1.1.1.275: (+)-trans-carveol dehydrogenase EC 1.1.1.276: serine 3-dehydrogenase (NADP+) EC 1.1.1.277: 3β-hydroxy-5β-steroid dehydrogenase EC 1.1.1.278: 3β-hydroxy-5α-steroid dehydrogenase EC 1.1.1.279: (R)-3-hydroxyacid-ester dehydrogenase EC 1.1.1.280: (S)-3-hydroxyacid-ester dehydrogenase EC 1.1.1.281: GDP-4-dehydro-6-deoxy-D-mannose reductase EC 1.1.1.282: Quinate/shikimate dehydrogenase EC 1.1.1.283: methylglyoxal reductase (NADPH-dependent) EC 1.1.1.284: S-(hydroxymethyl)glutathione dehydrogenase EC 1.1.1.285: 3′′-deamino-3′′-oxonicotianamine reductase EC 1.1.1.286: isocitrate—homoisocitrate dehydrogenase EC 1.1.1.287: D-arabinitol dehydrogenase (NADP+) EC 1.1.1.288: xanthoxin dehydrogenase EC 1.1.1.289: sorbose reductase EC 1.1.1.290: 4-phosphoerythronate dehydrogenase EC 1.1.1.291: 2-hydroxymethylglutarate dehydrogenase EC 1.1.1.292: 1,5-anhydro-D-fructose reductase (1,5-anhydro-D-mannitol-forming) EC 1.1.1.293: tropinone reductase I. This enzyme was already in the Enzyme List as EC 1.1.1.206, tropine dehydrogenase so EC 1.1.1.293 has been withdrawn at the public-review stage EC 1.1.1.294: chlorophyll(ide) b reductase EC 1.1.1.295: momilactone-A synthase EC 1.1.1.296: dihydrocarveol dehydrogenase EC 1.1.1.297: limonene-1,2-diol dehydrogenase EC 1.1.1.298: 3-hydroxypropionate dehydrogenase (NADP+) EC 1.1.1.299: malate dehydrogenase [NAD(P)+)] EC 1.1.1.300: NADP-retinol dehydrogenase EC 1.1.1.301: D-arabitol-phosphate dehydrogenase EC 1.1.1.302: 2,5-diamino-6-(ribosylamino)-4(3H)-pyrimidinone 5′-phosphate reductase EC 1.1.1.303: Diacetyl reductase ((R)-acetoin forming) EC 1.1.1.304: Diacetyl reductase ((S)-acetoin forming) EC 1.1.1.305: UDP-glucuronic acid dehydrogenase (UDP-4-keto-hexauronic acid decarboxylating) EC 1.1.1.306: S-(hydroxymethyl)mycothiol dehydrogenase EC 1.1.1.307: D-xylose reductase EC 1.1.1.308: sulfopropanediol 3-dehydrogenase EC 1.1.1.309: phosphonoacetaldehyde reductase (NADH) EC 1.1.1.310: (S)-sulfolactate dehydrogenase EC 1.1.1.311: (S)-1-phenylethanol dehydrogenase EC 1.1.1.312: 2-hydroxy-4-carboxymuconate semialdehyde hemiacetal dehydrogenase EC 1.1.1.313: sulfoacetaldehyde reductase EC 1.1.1.314: Now known to be catalyzed by EC 1.14.14.95, germacrene A hydroxylase EC 1.1.1.315: 11-cis-retinol dehydrogenase EC 1.1.1.316: L-galactose 1-dehydrogenase EC 1.1.1.317: perakine reductase EC 1.1.1.318: eugenol synthase EC 1.1.1.319: isoeugenol synthase EC 1.1.1.320: benzil reductase [(S)-benzoin forming] EC 1.1.1.321: benzil reductase [(R)-benzoin forming] EC 1.1.1.322: (–)-endo-fenchol dehydrogenase EC 1.1.1.323: (+)-thujan-3-ol dehydrogenase EC 1.1.1.324: 8-hydroxygeraniol dehydrogenase EC 1.1.1.325: sepiapterin reductase (L-threo-7,8-dihydrobiopterin forming) EC 1.1.1.326: zerumbone synthase EC 1.1.1.327: 5-exo-hydroxycamphor dehydrogenase EC 1.1.1.328: nicotine blue oxidoreductase EC 1.1.1.329: 2-deoxy-scyllo-inosamine dehydrogenase EC 1.1.1.330: very-long-chain 3-oxoacyl-CoA reductase EC 1.1.1.331: secoisolariciresinol dehydrogenase EC 1.1.1.332: chanoclavine-I dehydrogenase EC 1.1.1.333: decaprenylphospho-β-D-erythro-pentofuranosid-2-ulose 2-reductase EC 1.1.1.334: methylecgonone reductase EC 1.1.1.335: UDP-N-acetyl-2-amino-2-deoxyglucuronate dehydrogenase EC 1.1.1.336: UDP-N-acetyl-D-mannosamine dehydrogenase EC 1.1.1.337: L-2-hydroxycarboxylate dehydrogenase (NAD+) EC 1.1.1.338: (2R)-3-sulfolactate dehydrogenase (NADP+) EC 1.1.1.339: dTDP-6-deoxy-L-talose 4-dehydrogenase (NAD+) EC 1.1.1.340: 1-deoxy-11β-hydroxypentalenate dehydrogenase EC 1.1.1.341: CDP-abequose synthase EC 1.1.1.342: CDP-paratose synthase EC 1.1.1.343: phosphogluconate dehydrogenase (NAD+-dependent, decarboxylating) EC 1.1.1.344: dTDP-6-deoxy-L-talose 4-dehydrogenase [NAD(P)+] EC 1.1.1.345: D-2-hydroxyacid dehydrogenase (NAD+) EC 1.1.1.346: 2,5-didehydrogluconate reductase (2-dehydro-L-gulonate-forming) EC 1.1.1.347: geraniol dehydrogenase (NAD+) EC 1.1.1.348: (3R)-2′-hydroxyisoflavanone reductase EC 1.1.1.349: norsolorinic acid ketoreductase EC 1.1.1.350: ureidoglycolate dehydrogenase (NAD+) EC 1.1.1.351: phosphogluconate dehydrogenase [NAD(P)+-dependent, decarboxylating] EC 1.1.1.352: 5′-hydroxyaverantin dehydrogenase EC 1.1.1.353: versiconal hemiacetal acetate reductase EC 1.1.1.354: farnesol dehydrogenase (NAD+) EC 1.1.1.355: 2′-dehydrokanamycin reductase EC 1.1.1.356: GDP-L-colitose synthase EC 1.1.1.357: 3α-hydroxysteroid 3-dehydrogenase EC 1.1.1.358: 2-dehydropantolactone reductase EC 1.1.1.359: aldose 1-dehydrogenase [NAD(P)+] EC 1.1.1.360: glucose/galactose 1-dehydrogenase EC 1.1.1.361: glucose-6-phosphate 3-dehydrogenase EC 1.1.1.362: aklaviketone reductase EC 1.1.1.363: glucose-6-phosphate dehydrogenase [NAD(P)+] EC 1.1.1.364: dTDP-4-dehydro-6-deoxy-α-D-gulose 4-ketoreductase EC 1.1.1.365: D-galacturonate reductase EC 1.1.1.366: L-idonate 5-dehydrogenase (NAD+) EC 1.1.1.367: UDP-2-acetamido-2,6-β-L-arabino-hexul-4-ose reductase EC 1.1.1.368: 6-hydroxycyclohex-1-ene-1-carbonyl-CoA dehydrogenase EC 1.1.1.369: D-chiro-inositol 1-dehydrogenase EC 1.1.1.370: scyllo-inositol 2-dehydrogenase (NAD+) EC 1.1.1.371: scyllo-inositol 2-dehydrogenase (NADP+) EC 1.1.1.372: D/L-glyceraldehyde reductase EC 1.1.1.373: sulfolactaldehyde 3-reductase EC 1.1.1.374: UDP-N-acetylglucosamine 3-dehydrogenase EC 1.1.1.375: L-2-hydroxycarboxylate dehydrogenase [NAD(P)+] EC 1.1.1.376: L-arabinose 1-dehydrogenase [NAD(P)+] EC 1.1.1.377: L-rhamnose 1-dehydrogenase (NADP+) EC 1.1.1.378: L-rhamnose 1-dehydrogenase [NAD(P)+] EC 1.1.1.379: (R)-mandelate dehydrogenase EC 1.1.1.380: L-gulonate 5-dehydrogenase EC 1.1.1.381: 3-hydroxy acid dehydrogenase EC 1.1.1.382: ketol-acid reductoisomerase (NAD+) EC 1.1.1.383: ketol-acid reductoisomerase [NAD(P)+] EC 1.1.1.384: dTDP-3,4-didehydro-2,6-dideoxy-α-D-glucose 3-reductase EC 1.1.1.385: dihydroanticapsin dehydrogenase EC 1.1.1.386: ipsdienol dehydrogenase EC 1.1.1.387: L-serine 3-dehydrogenase (NAD+) EC 1.1.1.388: glucose-6-phosphate dehydrogenase (NAD+) EC 1.1.1.389: 2-dehydro-3-deoxy-L-galactonate 5-dehydrogenase EC 1.1.1.390: sulfoquinovose 1-dehydrogenase EC 1.1.1.391: 3β-hydroxycholanate 3-dehydrogenase (NAD+) EC 1.1.1.392: 3α-hydroxycholanate dehydrogenase (NADP+) EC 1.1.1.393: 3β-hydroxycholanate 3-dehydrogenase (NADP+) EC 1.1.1.394: aurachin B dehydrogenase EC 1.1.1.395: 3α-hydroxy bile acid-CoA-ester 3-dehydrogenase EC 1.1.1.396: bacteriochlorophyllide a dehydrogenase EC 1.1.1.397: β-methylindole-3-pyruvate reductase EC 1.1.1.398: 2-glutathionyl-2-methylbut-3-en-1-ol dehydrogenase EC 1.1.1.399: 2-oxoglutarate reductase EC 1.1.1.400: 2-methyl-1,2-propanediol dehydrogenase EC 1.1.1.401: 2-dehydro-3-deoxy-L-rhamnonate dehydrogenase (NAD+) EC 1.1.1.402: D-erythritol 1-phosphate dehydrogenase EC 1.1.1.403: D-threitol dehydrogenase (NAD+) EC 1.1.1.404: tetrachlorobenzoquinone reductase EC 1.1.1.405: ribitol-5-phosphate 2-dehydrogenase (NADP+) EC 1.1.1.406: galactitol 2-dehydrogenase (L-tagatose-forming) EC 1.1.1.407: D-altritol 5-dehydrogenase EC 1.1.1.408: 4-phospho-D-threonate 3-dehydrogenase EC 1.1.1.409: 4-phospho-D-erythronate 3-dehydrogenase EC 1.1.1.410: D-erythronate 2-dehydrogenase EC 1.1.1.411: L-threonate 2-dehydrogenase EC 1.1.1.412: 2-alkyl-3-oxoalkanoate reductase EC 1.1.1.413: A-factor type γ-butyrolactone 1′-reductase (1S-forming) EC 1.1.1.414: L-galactonate 5-dehydrogenase EC 1.1.1.415: noscapine synthase EC 1.1.1.416: isopyridoxal dehydrogenase (5-pyridoxolactone-forming) EC 1.1.1.417: 3β-hydroxysteroid-4β-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.418: plant 3β-hydroxysteroid-4α-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.419: nepetalactol dehydrogenase EC 1.1.1.420: D-apiose dehydrogenase EC 1.1.1.421: D-apionate oxidoisomerase EC 1.1.1.422: pseudoephedrine dehydrogenase EC 1.1.1.423: (1R,2S)-ephedrine 1-dehydrogenase EC 1.1.1.424: D-xylose 1-dehydrogenase (NADP+, D-xylono-1,4-lactone-forming) EC 1.1.1.425: levoglucosan dehydrogenase EC 1.1.1.426: UDP-N-acetyl-α-D-quinovosamine dehydrogenase
Sources: en.wikipedia.org
Weizmann's political efforts picked up speed, and on 10 December 1914 he met with Herbert Samuel, a British Cabinet member and a secular Jew who had studied Zionism; Samuel believed Weizmann's demands were too modest. Two days later, Weizmann met Balfour again, for the first time since their initial meeting in 1905; Balfour had been out of government ever since his electoral defeat in 1906, but remained a senior member of the Conservative Party in their role as Official Opposition. A month later, Samuel circulated a memorandum entitled The Future of Palestine to his Cabinet colleagues. The memorandum stated: "I am assured that the solution of the problem of Palestine which would be much the most welcome to the leaders and supporters of the Zionist movement throughout the world would be the annexation of the country to the British Empire". Samuel discussed a copy of his memorandum with Nathan Rothschild in February 1915, a month before the latter's death. It was the first time in an official record that enlisting the support of Jews as a war measure had been proposed. Many further discussions followed, including the initial meetings in 1915–16 between Lloyd George, who had been appointed Minister of Munitions in May 1915, and Weizmann, who was appointed as a scientific advisor to the ministry in September 1915. Seventeen years later, in his War Memoirs, Lloyd George described these meetings as being the "fount and origin" of the declaration; historians have rejected this claim.
Sulfur forms several polyatomic molecules. The best-known allotrope is octasulfur, cyclo-S8. The point group of cyclo-S8 is D4d and its dipole moment is 0 D. Octasulfur is a soft, bright-yellow solid that is odorless. It melts at 115.21 °C (239.38 °F), and boils at 444.6 °C (832.3 °F). At 95.2 °C (203.4 °F), below its melting temperature, cyclo-octasulfur begins slowly changing from α-octasulfur to the β-polymorph. The structure of the S8 ring is virtually unchanged by this phase transition, which affects the intermolecular interactions. Cooling molten sulfur freezes at 119.6 °C (247.3 °F), as it predominantly consists of the β-S8 molecules. Between its melting and boiling temperatures, octasulfur changes its allotrope again, turning from β-octasulfur to γ-sulfur, again accompanied by a lower density but increased viscosity due to the formation of polymers. At higher temperatures, the viscosity decreases as depolymerization occurs. Molten sulfur assumes a dark red color above 200 °C (392 °F). The density of sulfur is about 2 g/cm3, depending on the allotrope; all of the stable allotropes are excellent electrical insulators. The sublimation of sulfur becomes noticeable more or less between 20 °C (68 °F) and 50 °C (122 °F), and occurs readily in boiling water at 100 °C (212 °F). Sulfur is insoluble in water but soluble in carbon disulfide and, to a lesser extent, in other nonpolar organic solvents, such as benzene and toluene. Sulfur is also soluble in supercritical carbon dioxide.
Ribosomes from bacteria, archaea, and eukaryotes (in the three-domain system) resemble each other to a remarkable degree, evidence of a common origin. They differ in their size, sequence, structure, and the ratio of protein to RNA. The differences in structure allow some antibiotics to kill bacteria by inhibiting their ribosomes while leaving human ribosomes unaffected. In all domains, a polysome of two or more ribosomes may move along a single mRNA chain at one time, each reading a specific sequence and producing a corresponding protein molecule. The mitochondrial ribosomes (mitoribosomes) of eukaryotic cells are distinct from the other ribosomes. They functionally resemble those in bacteria, reflecting the evolutionary origin of mitochondria as endosymbiotic bacteria.
More than one million slaves were sold from the Upper South, which had a surplus of labour, and taken to the Deep South in a forced migration, splitting up many families. New communities of African American culture were developed in the Deep South, and the total slave population in the South eventually reached 4 million before liberation. In the 19th century, proponents of slavery often defended the institution as a "necessary evil". White people of that time feared that emancipation of black slaves would have more harmful social and economic consequences than the continuation of slavery. The French writer and traveler Alexis de Tocqueville, in Democracy in America (1835), expressed opposition to slavery while observing its effects on American society. He felt that a multiracial society without slavery was untenable, as he believed that prejudice against black people increased as they were granted more rights. Others, like James Henry Hammond argued that slavery was a "positive good" stating: "Such a class you must have, or you would not have that other class which leads progress, civilization, and refinement." The Southern state governments wanted to keep a balance between the number of slave and free states to maintain a political balance of power in Congress. The new territories acquired from Britain, France, and Mexico were the subject of major political compromises. By 1850, the newly rich cotton-growing South was threatening to secede from the Union, and tensions continued to rise.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.